{"product_id":"edwards-marketing-mix","title":"Edwards Lifesciences Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEdwards Lifesciences' 4P's Marketing Mix Analysis reveals how premium product innovation, value-based pricing, targeted clinical channels, and credibility-driven promotion combine to dominate cardiac markets. The preview highlights key tactics; the full, editable report delivers data, benchmarks, and ready-to-use slides for strategy or coursework—get it now. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTAVR valve platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences SAPIEN transcatheter aortic valve systems deliver minimally invasive replacement with proven durability supported by 5–8 year clinical data and broad anatomical fit for tricuspid and selected bicuspid cases. PARTNER-series outcomes show reduced length of stay to a median 1–2 days and improved quality‑of‑life metrics versus surgical AVR. Edwards holds north of 50% global TAVR share and differentiates via next‑gen delivery systems and expanding low‑risk indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgical valves \u0026amp; repair\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards offers surgical aortic and mitral valves including RESILIA tissue and complementary repair solutions designed for long-term performance. The portfolio emphasizes biocompatible materials, ease of implantation and durability supported by clinical follow-up beyond 5 years. Products are positioned for patients unsuitable for transcatheter approaches or requiring reoperation. A full suite of accessories and sizing tools supports efficient surgical workflow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTranscatheter mitral\/tricuspid\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences offers the PASCAL transcatheter repair\/replacement platform for MR and TR, emphasizing leaflet repair, controlled deployment and real-time echo\/fluoro compatibility. CLASP IID and CLASP TR trials demonstrated noninferiority to existing therapies with durable symptom relief and functional improvement at 1 year. Messaging targets high-risk surgical patients, highlighting rapid symptom reduction and shorter LOS. Ongoing pipeline work aims to expand treatable anatomies and device iterations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemodynamic monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdwards Lifesciences delivers advanced hemodynamic monitoring via FloTrac, Acumen HPI and Swan‑Ganz to support perioperative and ICU decision-making. The portfolio combines sensors, catheters and analytics software to provide predictive insights that help reduce complications and optimize fluid management. Solutions integrate with EMR and OR technologies for seamless, real-time data flow to clinicians.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProduct: FloTrac, Acumen HPI, Swan‑Ganz\u003c\/li\u003e\n\u003cli\u003eValue: predictive analytics for fluid optimization\u003c\/li\u003e\n\u003cli\u003eClinical impact: reduced complications, targeted resuscitation\u003c\/li\u003e\n\u003cli\u003eIntegration: EMR and OR interoperability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServices, training, digital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdwards bundles education, proctoring and clinical support to drive safe adoption of its valve and monitoring platforms, backed by a company reporting about $6.3B revenue in FY2024; offerings include planning software, imaging integration and case‑review tools, plus remote support and dashboards for performance improvement and active post‑market surveillance and physician community resources.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEducation + proctoring\u003c\/li\u003e\n\u003cli\u003ePlanning software \u0026amp; imaging\u003c\/li\u003e\n\u003cli\u003eRemote support \u0026amp; dashboards\u003c\/li\u003e\n\u003cli\u003ePost‑market surveillance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinimally invasive valves, repairs \u0026amp; analytics fuel \u003cstrong\u003e\u0026gt;50%\u003c\/strong\u003e TAVR share, \u003cstrong\u003e$6.3B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards’ product suite spans SAPIEN TAVR (5–8y durability data), surgical valves with RESILIA, PASCAL repair platform (CLASP noninferiority), and hemodynamic monitoring (FloTrac\/Acumen\/Swan‑Ganz), targeting minimally invasive care, surgical alternatives and perioperative analytics; \u0026gt;50% global TAVR share and $6.3B revenue in FY2024 drive adoption via training and integrated software.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eClinical impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAPIEN TAVR\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% TAVR share; 5–8y data\u003c\/td\u003e\n\u003ctd\u003eShorter LOS, QoL gains\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePASCAL\u003c\/td\u003e\n\u003ctd\u003eCLASP trials\u003c\/td\u003e\n\u003ctd\u003eDurable MR\/TR repair\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMonitoring\u003c\/td\u003e\n\u003ctd\u003eFloTrac\/Acumen\u003c\/td\u003e\n\u003ctd\u003ePredictive fluid mgmt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Edwards Lifesciences’ Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a clear breakdown of marketing positioning; grounded in real brand practices and competitive context, ready to repurpose for reports or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Edwards Lifesciences’ 4P marketing mix into a concise, leadership-ready snapshot that relieves information overload, aids rapid alignment, and is easily customized for presentations, cross-team workshops, or competitive comparisons.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect to hospitals\/IDNs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSell via specialized cardiovascular sales teams into cath labs, hybrid ORs and ICUs, focusing on the roughly 1,800 PCI-capable hospitals and 6,090 total US hospitals reported by AHA (2022). Target integrated delivery networks and academic centers to capture system-level contracts. Align with service-line leaders, cath lab managers and procurement for formulary placement. Support deals with capital planning for monitors and disposable supply continuity to reduce downtime and leakage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal footprint \u0026amp; access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards distributes products across North America, Europe, APAC and select LATAM\/MEA markets, with commercial presence in over 100 countries. Launches are staged by regulatory approvals and reimbursement readiness to protect adoption timelines. Logistics rely on regional warehouses and sterilized inventory flows to support hospital supply chains. Country-specific tendering and import rules dictate pricing and rollout cadence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical partnerships engage heart teams—interventional cardiologists, cardiac surgeons and anesthesiologists—through embedded in-procedure specialists and case support to improve procedural efficiency and outcomes. Collaborations with centers of excellence and structured proctoring accelerate adoption where TAVR now represents \u0026gt;60% of aortic valve procedures in the US. Referral pathways from echo labs and structural heart clinics funnel high-quality candidates into networked programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContracts \u0026amp; GPOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdwards leverages GPOs, tenders and long-term supply agreements for valves and disposables to secure hospital access and pricing; the company operates in more than 100 countries and reported annual revenue exceeding 6 billion USD in 2024. Consignment inventory programs support rapid case readiness while coordination with hospital value analysis committees optimizes product adoption. Service-level agreements ensure training coverage and equipment uptime targets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGPO\/tenders: negotiated pricing, contract terms\u003c\/li\u003e\n\u003cli\u003eConsignment: on-site inventory for OR readiness\u003c\/li\u003e\n\u003cli\u003eVAC coordination: clinical\/economic evaluation\u003c\/li\u003e\n\u003cli\u003eSLA: training, uptime, response times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEnable ordering via hospital ERP\/e-procurement portals, provide usage tracking, lot traceability and demand forecasting, integrate auto-replenishment for consigned kits, and offer digital documentation and IFUs to streamline compliance and reduce stockouts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eERP\/e-procurement integration\u003c\/li\u003e\n\u003cli\u003eUsage tracking \u0026amp; lot traceability\u003c\/li\u003e\n\u003cli\u003eDemand forecasting \u0026amp; auto-replenishment\u003c\/li\u003e\n\u003cli\u003eDigital IFUs \u0026amp; compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarget 1,800 PCI hospitals and 6,090 US hospitals to accelerate TAVR adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSell through specialized cardiovascular teams into cath labs, hybrid ORs and ICUs across ~1,800 PCI-capable and 6,090 total US hospitals (AHA 2022), targeting IDNs and academic centers for system contracts. Regional warehouses, consignment and GPO\/tender deals support rapid case readiness; launches follow regulatory\/reimbursement timing. Clinical proctoring, centers of excellence and referral pathways drive adoption; TAVR \u0026gt;60% US share; 2024 revenue \u0026gt;6B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospitals (total)\u003c\/td\u003e\n\u003ctd\u003e6,090 (AHA 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePCI-capable hospitals\u003c\/td\u003e\n\u003ctd\u003e~1,800\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAVR share (US)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial footprint\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eEdwards Lifesciences 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Edwards Lifesciences 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises. This full, editable document covers Product, Price, Place and Promotion with actionable insights and data-driven recommendations. Download is immediate and the file is ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164752785785,"sku":"edwards-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/edwards-marketing-mix.png?v=1762739500","url":"https:\/\/portersfiveforce.com\/products\/edwards-marketing-mix","provider":"Porter's Five Forces","version":"1.0","type":"link"}